Nanaimo-based Tilray, a medical cannabis research, cultivation and distribution company, announced today it has received the necessary permits to export medical cannabis flower for distribution to German patients.
This makes the Canadian company the first company with both flower and oil medical cannabis products available to the German market.
Tilray® Exports Bulk Supply of Medical Cannabis Flower to Germany https://t.co/zh5e5AGDLc
— Tilray Canada (@tilray) September 13, 2018
“Today’s announcement marks another milestone for Tilray as we expand operations in the European Union,” said Tilray CEO Brendan Kennedy in a press release, “We are proud to be able to offer access to differentiated high-quality, pharmaceutical-grade medical cannabis products to patients in need.”
Tilray’s full-spectrum cannabis extracts have already been available in German pharmacies nationwide since October 2017, through partnerships with German pharmaceutical wholesalers NOWEDA, GEHE, Alliance Healthcare, Pharma Privat and Phoenix in cooperation with pharma logistics partner Paesel + Lorei.
Tilray said its products offer higher potency for patients with specialized conditions.
This distribution comes after a UK-based patient suffering from a rare form of epilepsy was granted access to Tilray’s CBD oil.
The research conducted at The Hospital For Sick Children (SickKids) in Toronto, Canada last month lead to positive feedback for Tilray’s 2:100 CBD oil. The product was used as the primary medicine for children with drug-resistant epilepsy (DRE) due to Dravet Syndrome.
The company said that more updates on how patients in Germany can access Tilray’s whole flower products will be released later this year.